Vaderis raises $152.0M Series B (Switzerland, Aug 2026)
$152.0M
$152m Series BGenerated social card
Headline
Vaderis bags $152m Series B - BioXconomy
About
Vaderis is a biotechnology company focused on developing treatments for rare diseases, specifically hereditary hemorrhagic telangiectasia (HHT). The company has recently closed a $152 million Series B financing round to support the advancement of its investigational therapy, engasertib, which targets the underlying causes of HHT. This funding will enable Vaderis to conduct a Phase III clinical trial for this promising treatment option.
Article summary
Vaderis bags $152m Series B BioXconomy
Founder
Azmi Nabulsi
President and CEO
Investors · 8
6 hiddenRelated rounds
| Aug 14, 2026 | Aisot Technologies | $2.3M | — | Switzerland |
| Aug 12, 2026 | Zerolook | $1.9M | Pre-seed | Switzerland |
| Aug 04, 2026 | Exclaim Robotics | $5.0M | Seed | Switzerland |
| Jul 28, 2026 | ZuriQ | $24.0M | — | Switzerland |